MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.…
MBX Biosciences (MBX) Stock Looks Above Fair Value On Phase 3 Progress
Is MBX Biosciences (MBX) Still Undervalued After Its Pullback From A Strong 1 Year Run?
MBX Biosciences (NASDAQ: MBX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 63 employees.
The shares were at 49.55 USD on 20 November 2026, up 80.9% over 52 weeks. Its 52-week range is 26.00 USD to 72.64 USD: the price is 31.8% below the high and 90.6% above the low.
Its market capitalisation is 2.46B USD.
MBX Biosciences reports return on equity of -23.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 478.30M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 11 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 95.09 USD is 91.9% above the current price. The next earnings report is expected on 18 March 2027.